US 11,981,922 B2
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
Meromit Singer, Boston, MA (US); Aviv Regev, Cambridge, MA (US); Orit Rozenblatt-Rosen, Cambridge, MA (US); Davide Mangani, Boston, MA (US); Ana Carrizosa Anderson, Boston, MA (US); Vijay K. Kuchroo, Boston, MA (US); and Linglin Huang, Boston, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US); The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed on Oct. 5, 2020, as Appl. No. 17/063,604.
Claims priority of provisional application 62/910,340, filed on Oct. 3, 2019.
Prior Publication US 2021/0102168 A1, Apr. 8, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/38 (2006.01); C07K 16/40 (2006.01); C12N 5/0783 (2010.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01)
CPC C12N 5/0638 (2013.01) [A61K 35/17 (2013.01); A61K 39/39541 (2013.01); A61K 39/3955 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C07K 16/38 (2013.01); C07K 16/40 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/507 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01)] 14 Claims
 
1. A method of cancer treatment comprising administering to a subject in need thereof CD8 T cells genetically modified ex vivo to decrease or eliminate expression, activity or function of NRP1, wherein a tumor sample obtained from the subject comprises tumor cells that express VEGFB and CD8 T cells that express NRP1, and wherein the method further comprises detecting the expression of VEGFB on tumor cells obtained from the subject, whereby only subjects comprising tumor cells that express VEGFB are treated.